Skip to content
Yog Pharma
Central nervous systemNorepinephrine-dopamine reuptake inhibitor

Bupropion Hydrochloride is a norepinephrine-dopamine reuptake inhibitor indicated for major depressive disorder, seasonal affective disorder and smoking cessation. We supply it to US manufacturers of tablets, sustained-release tablets and extended-release tablets.

CAS31677-93-7276.2 g/molC13H19Cl2NO
2D structure of Bupropion Hydrochloride, shown as the active moiety without counter-ion or water of hydration.

Data from PubChem (CID 62884) and FDA’s substance registry

CAS number

31677-93-7

Molecular formula

C13H19Cl2NO

Molecular weight

276.2g/mol

FDA UNII

IUPAC name

2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one;hydrochloride

InChIKey

HEYVINCGKDONRU-UHFFFAOYSA-N

Appearance
White or almost white crystalline powder.
Solubility
Freely soluble in water, and soluble in alcohol and in 0.1 N hydrochloric acid.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Hygroscopic and prone to degrade with moisture, so water content and packaging matter. Most demand is for extended-release tablets.

On the US market

Reference product
WellbutrinNDA 018644
Approved ANDAs
38 with a marketed product
Approved forms and strengths
  • Extended-release tablet 100 mg, 150 mg, 200 mg, 300 mg, 450 mg
  • Tablet 75 mg, 100 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com